3.238EUR-3.63%Mkt Cap: 958.23M EURP/E: —Last update: 2026-06-01
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherap…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap958.23M EUR
Enterprise Value771.17M EUR
Revenue (TTM)5.74M EUR
Gross Profit5.74M EUR
Net Income (TTM)-146.95M EUR
Revenue/Share0.0260 EUR
Last Price3.238 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees161
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-40.00
PEG—
EV/EBITDA-4.67
EV/Revenue134.44
P/S173.35
P/B5.55
EPS (TTM)-0.77
EPS (Forward)-0.08
52W Range
1.39259% of range4.500
52W High4.500 EUR
52W Low1.392 EUR
Profitability
Gross Margin100.00%
Oper. Margin-5311.11%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.07%
ROA-62.87%
Growth
Revenue Growth12.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-121.18M EUR
CapEx (TTM)538.00K EUR
FCF Margin-1520.33%
FCF Yield-9.10%
Net Debt-223.10M EUR
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.05
Current Ratio4.76
Quick Ratio4.72
Book Value/Sh0.6059 EUR
Cash/Share0.7750 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.800 EUR
Target Range1.000 EUR – 5.500 EUR
# Analysts3
Ownership
Shares Out.295.93M
Float176.27M
Insiders0.09%
Institutions54.41%
Technical
SMA 503.461 (-6.4%)
SMA 2002.978 (+8.7%)
Beta-0.24
S&P 52W Chg27.94%
Avg Vol (30d)934.79K
Avg Vol (10d)682.10K
Technical Indicators
RSI (14)50.0
MACD-0.0656
MACD Signal-0.0704
MACD Hist.+0.0048
BB Upper3.532 EUR
BB Middle3.330 EUR
BB Lower3.129 EUR
BB Width12.11%
ATR (14)0.1614 EUR
Vol Ratio (20d)8.51x